Figure 4. Sirolimus treatment leads to prolonged enhancement of antigen-specific CD8⁺ T_CM cells.

RM were treated with sirolimus or left untreated during both vaccination and boost with MVA (n=4 in each group). PBMCs isolated at each timepoint were stimulated with vaccinia virus and assessed for IFN-γ and TNF. Percentage of dual TNF and IFN-γ producing CD8⁺ T cells within the T_EFF/EM (A) vs T_CM (B) subsets are shown. T_CM cells were defined as CD3⁺ CD8⁺ CD28⁺CD95⁺; T_EM cells are CD3⁺ CD8⁺ CD28⁻CD95⁺. p<0.05 for comparisons between sirolimus-treated and untreated controls for each timepoint within both the T_EFF/EM and T_CM subsets.